Letter to Editor
Acute Demyelinating Polyneuropathy Caused by Nivolumab in a Man with Metastatic Non-Small Cell Lung CancerButt Sabeeh-Ur-Rehman1* and Shah Bhaumik2
- *Corresponding Author:
- Butt Sabeeh-Ur-Rehman
Department of Neurology
Ballarat Base Hospital
Drummond Street North, Ballarat Central
VIC, 3350, Australia
E-mail: [email protected]
Received Date: March 14, 2016; Accepted Date: April 19, 2016; Published Date: May 19, 2016
Citation: Butt SUR, Bhaumik S (2016) Acute Demyelinating Polyneuropathy Caused by Nivolumab in a Man with Metastatic Non-Small Cell Lung Cancer. J Gerontol Geriatr Res 5:302. doi:10.4172/2167-7182.1000302
Copyright: © 2016 Butt SUR, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Immune checkpoint inhibitors include programmed cell death-1 receptor inhibitors (PD-1), programmed cell death ligand-1 inhibitors and CTLA-4 inhibitors and are novel treatment against certain cancers like non-small cell lung cancer (NSCLC), melanoma and renal cell cancer. They act by boosting the immune response against cancer cells and have improved the prognosis of patients with these cancers significantly shifting the treatment paradigm.